Ken Fisher's ABT Position Overview
Ken Fisher (via Fisher Asset Management, LLC) currently holds 752,105 shares of Abbott Laboratories (ABT) worth $77.22 M, representing 0.03% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 52 quarters.
Based on 13F filings since 2013, Ken Fisher has maintained a long-term strategic position in ABT, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2020, adding 3.34 M shares. Largest reduction occurred in Q1 2026, reducing 10.69 M shares.
Analysis based on 13F filings available since 2013 Q2
Ken Fisher's Abbott Laboratories (ABT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Abbott Laboratories (ABT) Trades by Ken Fisher
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -10.69 M | Reduce 93.43% | 752,105 | $102.67 |
| Q4 2025 | -592,629 | Reduce 4.93% | 11.44 M | $125.29 |
| Q3 2025 | +170,061 | Add 1.43% | 12.03 M | $133.94 |
| Q2 2025 | +209,610 | Add 1.80% | 11.86 M | $136.01 |
| Q1 2025 | +376,090 | Add 3.33% | 11.65 M | $132.65 |
| Q4 2024 | +174,919 | Add 1.58% | 11.28 M | $113.11 |
| Q3 2024 | +585,915 | Add 5.57% | 11.1 M | $114.01 |
| Q2 2024 | +324,480 | Add 3.18% | 10.52 M | $103.91 |
| Q1 2024 | +269,639 | Add 2.72% | 10.19 M | $113.66 |
| Q4 2023 | +228,039 | Add 2.35% | 9.92 M | $110.07 |
| Q3 2023 | +26,735 | Add 0.28% | 9.69 M | $96.85 |
| Q2 2023 | +200,326 | Add 2.12% | 9.67 M | $109.02 |
| Q1 2023 | +164,429 | Add 1.77% | 9.47 M | $101.26 |
| Q4 2022 | +174,002 | Add 1.91% | 9.3 M | $109.79 |
| Q3 2022 | -261,727 | Reduce 2.79% | 9.13 M | $96.76 |
| Q2 2022 | +276,309 | Add 3.03% | 9.39 M | $108.65 |
| Q1 2022 | +351,289 | Add 4.01% | 9.11 M | $118.36 |
| Q4 2021 | +386,089 | Add 4.61% | 8.76 M | $140.74 |
| Q3 2021 | +274,915 | Add 3.39% | 8.38 M | $118.13 |
| Q2 2021 | +318,244 | Add 4.09% | 8.1 M | $115.93 |
| Q1 2021 | +297,491 | Add 3.97% | 7.78 M | $119.84 |
| Q4 2020 | +329,909 | Add 4.61% | 7.49 M | $109.49 |
| Q3 2020 | +251,776 | Add 3.65% | 7.16 M | $108.83 |
| Q2 2020 | +3.34 M | Add 93.73% | 6.9 M | $91.43 |
| Q1 2020 | +3.29 M | Add 1199.24% | 3.56 M | $78.91 |
| Q4 2019 | -125,020 | Reduce 31.31% | 274,305 | $86.86 |
| Q3 2019 | -947 | Reduce 0.24% | 399,325 | $83.67 |
| Q2 2019 | -8,430 | Reduce 2.06% | 400,272 | $84.10 |
| Q1 2019 | -23,344 | Reduce 5.40% | 408,702 | $79.94 |
| Q4 2018 | +4,584 | Add 1.07% | 432,046 | $72.33 |
| Q3 2018 | +18,009 | Add 4.40% | 427,462 | $73.36 |
| Q2 2018 | +5,296 | Add 1.31% | 409,453 | $60.99 |
| Q1 2018 | +92,188 | Add 29.55% | 404,157 | $59.92 |
| Q4 2017 | -34,536 | Reduce 9.97% | 311,969 | $57.07 |
| Q3 2017 | +3,095 | Add 0.90% | 346,505 | $53.36 |
| Q2 2017 | +326,754 | Add 1961.78% | 343,410 | $48.61 |
| Q1 2017 | +1,862 | Add 12.59% | 16,656 | $44.43 |
| Q4 2016 | +2,359 | Add 18.97% | 14,794 | $38.39 |
| Q3 2016 | +48 | Add 0.39% | 12,435 | $42.30 |
| Q2 2016 | -3,026 | Reduce 19.63% | 12,387 | $42.14 |
| Q1 2016 | -1,873 | Reduce 10.84% | 15,413 | $43.40 |
| Q4 2015 | +2,032 | Add 13.32% | 17,286 | $44.89 |
| Q3 2015 | +260 | Add 1.73% | 15,254 | $40.25 |
| Q2 2015 | +1,899 | Add 14.50% | 14,994 | $49.09 |
| Q1 2015 | -733 | Reduce 5.30% | 13,095 | $46.35 |
| Q4 2014 | +2,567 | Add 22.80% | 13,828 | $45.05 |
| Q3 2014 | -6,766 | Reduce 37.53% | 11,261 | $41.56 |
| Q2 2014 | +9,281 | Add 106.12% | 18,027 | $40.88 |
| Q1 2014 | +1,101 | Add 14.40% | 8,746 | $38.53 |
| Q4 2013 | -794 | Reduce 9.41% | 7,645 | $38.33 |
| Q3 2013 | -2,246 | Reduce 21.02% | 8,439 | $33.18 |
| Q2 2013 | +10,685 | Add 0.00% | 10,685 | $34.91 |
Ken Fisher's Abbott Laboratories Investment FAQs
Ken Fisher first purchased Abbott Laboratories (ABT) in Q2 2013, acquiring 10,685 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher has held Abbott Laboratories (ABT) for 52 quarters since Q2 2013.
Ken Fisher's largest addition to Abbott Laboratories (ABT) was in Q2 2020, adding 6,904,344 shares worth $631.26 M.
According to the latest 13F filing for Q1 2026, Ken Fisher's firm, Fisher Asset Management, LLC, owns 752,105 shares of Abbott Laboratories (ABT), valued at approximately $77.22 M.
As of the Q1 2026 filing, Abbott Laboratories (ABT) represents approximately 0.03% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings.
Ken Fisher's peak holding in Abbott Laboratories (ABT) was 12,032,884 shares, as reported at the end of Q3 2025.